论文部分内容阅读
该文应用超微量肝素对重症新生儿硬肿症进行治疗研究，资料表明：治疗组临床症状：体温、哭声低下或不哭、尿少或无尿、呼吸困难、肺出血恢复正常时间以及皮肤硬肿、皮肤苍白或青紫、四肢或全身冰冷、心率增快或减慢以及低血压恢复正常时间均比对照组为早（Ｐ＜０．０１）；吮乳困难与肢体活动恢复正常时间、脉细弱恢复正常时间也均比对照组早（Ｐ＜０．０５）。治疗组血生化检测高钠血症、代谢性酸中毒以及高尿素氮质血症恢复正常时间均比对照组为早（Ｐ＜０．００５）；高钾血症与低血糖症恢复正常时间也比对照组为早（Ｐ＜０．０２）。超微量肝素疗法使用简便、经济、不需凝血检测监护、且安全无副作用、临床易于推广，为今后研究重症新生儿硬肿症提供新的治疗措施。
The application of ultra-trace amount of heparin on severe neonatal sclerema treatment study, the data show that: the treatment group clinical symptoms: body temperature, crying low or no cry, oliguria or anuria, dyspnea, pulmonary hemorrhage return to normal time and the skin Edema, pale skin or bruising, cold limbs or whole body, faster or slower heart rate and normal time of hypotension recovery than those in control group (P <0.01); difficulty in sucking milk and recovery of normal limbs and veins Weak recovery time is also earlier than the control group (P <0.05). Blood biochemical detection of hypernatremia, metabolic acidosis and high return of azotemia in the treatment group were earlier than those in the control group (P <0.005); hyperkalemia and hypoglycemia returned to normal As early as the control group (P <0.02). Ultra-trace amount of heparin therapy is easy to use, economical, without coagulation test monitoring, and safe without side effects, clinical easy to promote, provide new treatment measures for the study of severe neonatal sclera in the future.